You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Active isomer of (RS)-MCPG. Non-selective group I/group II metabotropic glutamate receptor antagonist.
Racemate also available.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 209.2. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||4.78 mL||23.9 mL||47.8 mL|
|5 mM||0.96 mL||4.78 mL||9.56 mL|
|10 mM||0.48 mL||2.39 mL||4.78 mL|
|50 mM||0.1 mL||0.48 mL||0.96 mL|
References are publications that support the biological activity of the product.
Bordi et al (1996) Effects of the metabotropic glutamate receptor antagonist MCPG on spatial and context-specific learning. Neuropharmacology 35 1557 PMID: 9025103
Collingridge and Watkins (1994) Phenylglycine derivatives as metabotropic glutamate receptor antagonists. TiPS 15 333 PMID: 7992387
Jane et al (1993) Stereospecific antagonism by (+)-α-methyl-4-carboxyphenylglycine (MCPG) of 1S,3R-ACPD induced effects in neonatal rat motoneurones and rat thalamic neurones. Neuropharmacology 32 725 PMID: 7689710
Sekiyama et al (1996) Structure-activity relationships of new agonists and antagonists of different metabotropic glutamate receptor subtypes. Br. J. Pharmacol. 117 1493 PMID: 8730745
If you know of a relevant reference for (S)-MCPG, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: (S)-MCPG, (S)-MCPG supplier, mGlur, Group, I, Receptors, mGlu1, mGlu5, mGluR1, mGluR5, Glutamate, Metabotropic, II, mGlu2, mGlu3, mGluR2, mGluR3, antagonists, Non-selective, mGlu, 0337, Tocris Bioscience
24 Citations for (S)-MCPG
Citations are publications that use Tocris products. Selected citations for (S)-MCPG include:
Fukunaga et al (2007) Potent and specific action of the mGlu1 antagonists YM-298198 and JNJ16259685 on synaptic transmission in rat cerebellar slices. Br J Pharmacol 151 870 PMID: 17502847
Szokol et al (2015) Augmentation of Ca(2+) signaling in astrocytic endfeet in the latent phase of temporal lobe epilepsy. Elife 9 49 PMID: 25762896
Rosa et al (2015) Neuron-glia signaling in developing retina mediated by neurotransmitter spillover. J Neurosci 4 PMID: 26274565
Stephen et al (2015) Miro1 Regulates Activity-Driven Positioning of Mitochondria within Astrocytic Processes Apposed to Synapses to Regulate Intracellular Calcium Signaling. Proc Natl Acad Sci U S A 35 15996 PMID: 26631479
Huang and Hsu (2010) Activation of muscarinic acetylcholine receptors induces a nitric oxide-dependent long-term depression in rat medial prefrontal cortex. Cereb Cortex 20 982 PMID: 19666830
Reissner et al (2010) A novel postsynaptic mechanism for heterosynaptic sharing of short-term plasticity. J Neurosci 30 8797 PMID: 20592201
Melyan et al (2004) Metabotropic regulation of intrinsic excitability by synaptic activation of kainate receptors. J Neurosci 24 4530 PMID: 15140923
Kumar and Foster (2004) Enhanced long-term potentiation during aging is masked by processes involving intracellular calcium stores. J Neurophysiol 91 2437 PMID: 14762159
Melis et al (2004) Prefrontal cortex stimulation induces 2-arachidonoyl-glycerol-mediated suppression of excitation in DA neurons. J Neurosci 24 10707 PMID: 15564588
Bagayogo and Dreyfus (2009) Regulated release of BDNF by cortical oligodendrocytes is mediated through metabotropic glutamate receptors and the PLC pathway. ASN Neuro 1 PMID: 19570026
Paladini et al (2003) DA controls the firing pattern of DA neurons via a network feedback mechanism. Nat Neurosci 100 2866 PMID: 12604788
Matthies et al (2000) Enhancement of glutamate release by L-fucose changes effects of glutamate receptor antagonists on long-term potentiation in the rat hippocampus. Learn Mem 7 227 PMID: 10940323
Min et al (1999) Synaptically released glutamate reduces gamma-aminobutyric acid (GABA)ergic inhibition in the hippocampus via kainate receptors. Proc Natl Acad Sci U S A 96 9932 PMID: 10449797
Vogt and Nicoll (1999) Glutamate and gamma-aminobutyric acid mediate a heterosynaptic depression at mossy fiber synapses in the hippocampus. Proc Natl Acad Sci U S A 96 1118 PMID: 9927703
Dunaevsky et al (1999) Developmental regulation of spine motility in the mammalian central nervous system. Proc Natl Acad Sci U S A 96 13438 PMID: 10557339
Colwell et al (1996) Regulation of N-MthD.-aspartate-induced toxicity in the neostriatum: a role for metabotropic glutamate receptors? Front Cell Neurosci 93 1200 PMID: 8577740
Nieus et al (2014) Regulation of output spike patterns by phasic inhibition in cerebellar granule cells. Front Cell Neurosci 8 246 PMID: 25202237
Gu et al (2015) miR-26a and miR-384-5p are required for LTP maintenance and spine enlargement. Nat Commun 6 6789 PMID: 25858512
Ali (2011) CB1 modulation of temporally distinct synaptic facilitation among local circuit interneurons mediated by N-type calcium channels in CA1. J Neurophysiol 105 1051 PMID: 21123660
Navarrete et al (2012) Astrocytes mediate in vivo cholinergic-induced synaptic plasticity. PLoS Biol 10 e1001259 PMID: 22347811
Akerboom et al (2012) Optimization of a GCaMP calcium indicator for neural activity imaging. J Neurosci 32 13819 PMID: 23035093
Platt et al (2012) Striatal DA transmission is subtly modified in human A53Tα-synuclein overexpressing mice. PLoS One 7 e36397 PMID: 22570709
Shinoda et al (2010) Persistent synapse loss induced by repetitive LTD in developing rat hippocampal neurons. PLoS One 5 e10390 PMID: 20436928
Bender et al (2006) Two coincidence detectors for spike timing-dependent plasticity in somatosensory cortex. J Neurosci 26 4166 PMID: 16624937
Do you know of a great paper that uses (S)-MCPG from Tocris? Please let us know.
Reviews for (S)-MCPG
Average Rating: 5 (Based on 1 Review.)
Have you used (S)-MCPG?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
When mGluRs were suppressed with 1 mM (S)-MCPG, NMDAR effect was not enough powerful to generate action potentials in response to repetitive electrical stimulation of neural tissue. Figure: evoked post-synaptic potentials with action potentials (under control) and without action potentials (after application of MCPG.
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.